Harnessing the power of RNA epigenetics

Watch full video

STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.

Read more

RNA and RNA epigenetics

RNA (ribonucleic acid) is the only direct product of the human genome and one type of RNA, mRNA, acts as the template for the synthesis of all proteins, the molecular machines of the cell. RNA is also known to be a key player in cellular decision-making, particularly in the form of non-coding RNA (ncRNA) such as microRNA, piRNA and long non-coding RNA.

Read more

View video

News

Scrip Intelligence: STORM’s METTL3 Inhibitor Effective Against AML

STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML

Events

RNA Epigenetics in Human Disease

A STORM Therapeutics conference | 2022 Dates To be Confirmed